Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Carboplatin + DNIB0600A|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|DNIB0600A||Lifastuzumab vedotin|RG-7599||DNIB0600A (Lifastuzumab vedotin) is an antibody-drug conjugate consists of an antibody targeting SLC34A2 and monomethyl auristatin E, which may lead to disruption of the microtubule network in SLC34A2-expressing cancer cells, thereby potentially inhibiting cell proliferation (PMID: 29401246, PMID: 32534811, PMID: 31540980).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||Bevacizumab + Carboplatin + DNIB0600A||Phase I||Actionable||In a Phase Ib trial, the combination of DNIB0600A (Lifastuzumab vedotin) and Paraplatin (carboplatin) with or without Avastin (bevacizumab) demonstrated safety in patients with recurrent ovarian cancer and resulted in an objective response rate (ORR) of 59% (24/41), with a median progression-free survival (PFS) of 10.7 months, while the combination with Avastin (bevacizumab) resulted in an ORR of 67% (8/12) and a median PFS of 13.9 months (PMID: 32534811; NCT01995188).||32534811|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01995188||Phase I||Bevacizumab + Carboplatin + DNIB0600A Carboplatin + DNIB0600A||A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer||Completed||USA||0|